Research programme: monoclonal T cell receptor therapeutics - MediGene Ltd
Alternative Names: Monoclonal TCRs; mTCRs; SurDex; TaxoDexLatest Information Update: 27 Dec 2022
Price :
$50 *
At a glance
- Originator Avidex
- Developer MediGene Ltd
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Bladder cancer; Leukaemia; Lung cancer; Pancreatic cancer; Prostate cancer; Viral infections
Most Recent Events
- 27 Dec 2022 Discontinued - Preclinical for Autoimmune disorders in United Kingdom (unspecified route)
- 27 Dec 2022 Discontinued - Preclinical for Leukaemia in United Kingdom (unspecified route)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in United Kingdom